Literature DB >> 20532788

[Novel approach for the early detection of inflammatory rheumatic diseases in the population using a mobile screening unit].

J Heinert1, C Iking-Konert, M Blumenroth, O Sander, J Richter, M Schneider.   

Abstract

Current evidence-based guidelines for patients with rheumatoid arthritis (RA) emphasize the need for early diagnosis and treatment with disease-modifying antirheumatic drugs. However, these recommendations have not been implemented universally in Germany. This prompted the German Cooperative Rheumatology Group Rhine-Ruhr to devise a screening programme for inflammatory rheumatic diseases (IRD) using a specially equipped bus, which was sent on a 5-week tour of a series on local towns. Visitors were asked to fill out a questionnaire (RheumaCheck) and to undergo a blood test for rheumatoid factor and anti-mutated citrullinated vimentin antibodies. In the case of positive test results or on request due to symptoms, visitors could undergo targeted examination on the bus by a rheumatologist. Of the 2691 people who visited the bus (73% females, average age 62 years), 1330 consulted the rheumatologist. IRD was suspected in 319 attendees and confirmed in 104 of 172 screening participants, who went on to attend a rheumatological practice. RA was diagnosed in a total of 54 cases (2.1% of all visitors).

Entities:  

Mesh:

Year:  2010        PMID: 20532788     DOI: 10.1007/s00393-010-0653-x

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  12 in total

1.  Rheumatoid arthritis in a population sample.

Authors:  J H KELLGREN; J S LAWRENCE
Journal:  Ann Rheum Dis       Date:  1956-03       Impact factor: 19.103

2.  Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.

Authors:  Linda Mathsson; Mohammed Mullazehi; Marius C Wick; Olof Sjöberg; Ronald van Vollenhoven; Lars Klareskog; Johan Rönnelid
Journal:  Arthritis Rheum       Date:  2008-01

3.  Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

Authors:  Timo Möttönen; Pekka Hannonen; Markku Korpela; Martti Nissilä; Hannu Kautiainen; Jorma Ilonen; Leena Laasonen; Oili Kaipiainen-Seppänen; Per Franzen; Tapani Helve; Juhani Koski; Marianne Gripenberg-Gahmberg; Riitta Myllykangas-Luosujärvi; Marjatta Leirisalo-Repo
Journal:  Arthritis Rheum       Date:  2002-04

4.  Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis.

Authors:  R Peltomaa; L Paimela; H Kautiainen; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

5.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

Authors:  Charles G Helmick; David T Felson; Reva C Lawrence; Sherine Gabriel; Rosemarie Hirsch; C Kent Kwoh; Matthew H Liang; Hilal Maradit Kremers; Maureen D Mayes; Peter A Merkel; Stanley R Pillemer; John D Reveille; John H Stone
Journal:  Arthritis Rheum       Date:  2008-01

6.  The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century.

Authors:  D Symmons; G Turner; R Webb; P Asten; E Barrett; M Lunt; D Scott; A Silman
Journal:  Rheumatology (Oxford)       Date:  2002-07       Impact factor: 7.580

Review 7.  [The National Database of the German Arthritis Centres--a 12 year balance].

Authors:  A Zink; D Huscher; M Schneider
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

8.  Advance and unmet need of health care for patients with rheumatoid arthritis in the German population--results from the German Rheumatoid Arthritis Population Survey (GRAPS).

Authors:  Gisela Westhoff; Matthias Schneider; Heiner Raspe; Henning Zeidler; Claus Runge; Timm Volmer; Angela Zink
Journal:  Rheumatology (Oxford)       Date:  2009-03-25       Impact factor: 7.580

9.  Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.

Authors:  Lena Innala; Heidi Kokkonen; Catharina Eriksson; Erik Jidell; Ewa Berglin; Solbritt Rantapää Dahlqvst
Journal:  J Rheumatol       Date:  2008-04-01       Impact factor: 4.666

10.  [RheumaCheck: development and evaluation of a German language screening instrument for rheumatic diseases].

Authors:  Jutta G Richter; Ewa Wessel; Ralf Klimt; Reinhardt Willers; Matthias Schneider
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

View more
  1 in total

Review 1.  [Rheumatology in the mirror of media and advertising exemplified by the Rheumazentrum Rhein-Ruhr].

Authors:  O Sander; W Korfmacher; B Ostendorf; M Schneider
Journal:  Z Rheumatol       Date:  2018-05       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.